A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma

Giovanni Lughezzani, Claudio Jeldres, Hendrik Isbarn, Shahrokh F. Shariat, Maxine Sun, Daniel Pharand, Hugues Widmer, Philippe Arjane, Markus Graefen, Francesco Montorsi, Paul Perrotte, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

Abstract

Objectives: To perform a population-based analysis of the potential staging or prognostic value (or both) of lymph node dissection (LND) in patients without nodal metastases vs no LND. In several previous reports, LND in patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy (NU) was associated with better survival relative to no LND (pNx), even in the absence of pathologically confirmed nodal metastases (pN0). Methods: Within the surveillance, epidemiology, and end results database, we identified 2824 patients treated with NU for UTUC between 1988 and 2004. CSM rates after NU were graphically explored using Kaplan-Meier plots. Univariable and multivariable Cox regression models tested the effect of N0 vs Nx stage on CSM, after adjusting for T stage, tumor grade, age, gender, primary tumor location, type, and year of surgery. Results: The CSM-free survival rate at 5 years after NU was 81.2% and 77.8% respectively for pN0 and pNx patients. In univariable analyses pNx vs pN0 status was not associated with worse survival (HR: 1.19; P = .09). After adjustment for all covariates, pNx vs pN0 status still failed to achieve independent predictor status (HR: 0.99; P = .9). Conclusions: We found no survival benefit related to the performance of LND in pN0 patients, relative to pNx patients. Lack of standardized criteria for patients' selection for LND and for pathological lymph node specimen evaluation represents some of the explanation for the observed discrepancy between the current finding and previous findings. Crown

Original languageEnglish
Pages (from-to)118-124
Number of pages7
JournalUrology
Volume75
Issue number1
DOIs
Publication statusPublished - Jan 2010

Fingerprint

Lymph Node Excision
Carcinoma
Survival
Neoplasm Metastasis
Crowns
Proportional Hazards Models
Patient Selection
Neoplasms
Epidemiology
Survival Rate
Lymph Nodes
Databases
Population

ASJC Scopus subject areas

  • Urology

Cite this

A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma. / Lughezzani, Giovanni; Jeldres, Claudio; Isbarn, Hendrik; Shariat, Shahrokh F.; Sun, Maxine; Pharand, Daniel; Widmer, Hugues; Arjane, Philippe; Graefen, Markus; Montorsi, Francesco; Perrotte, Paul; Karakiewicz, Pierre I.

In: Urology, Vol. 75, No. 1, 01.2010, p. 118-124.

Research output: Contribution to journalArticle

Lughezzani, G, Jeldres, C, Isbarn, H, Shariat, SF, Sun, M, Pharand, D, Widmer, H, Arjane, P, Graefen, M, Montorsi, F, Perrotte, P & Karakiewicz, PI 2010, 'A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma', Urology, vol. 75, no. 1, pp. 118-124. https://doi.org/10.1016/j.urology.2009.07.1296
Lughezzani, Giovanni ; Jeldres, Claudio ; Isbarn, Hendrik ; Shariat, Shahrokh F. ; Sun, Maxine ; Pharand, Daniel ; Widmer, Hugues ; Arjane, Philippe ; Graefen, Markus ; Montorsi, Francesco ; Perrotte, Paul ; Karakiewicz, Pierre I. / A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma. In: Urology. 2010 ; Vol. 75, No. 1. pp. 118-124.
@article{670103f126d0436e916ef84090ea12ac,
title = "A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma",
abstract = "Objectives: To perform a population-based analysis of the potential staging or prognostic value (or both) of lymph node dissection (LND) in patients without nodal metastases vs no LND. In several previous reports, LND in patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy (NU) was associated with better survival relative to no LND (pNx), even in the absence of pathologically confirmed nodal metastases (pN0). Methods: Within the surveillance, epidemiology, and end results database, we identified 2824 patients treated with NU for UTUC between 1988 and 2004. CSM rates after NU were graphically explored using Kaplan-Meier plots. Univariable and multivariable Cox regression models tested the effect of N0 vs Nx stage on CSM, after adjusting for T stage, tumor grade, age, gender, primary tumor location, type, and year of surgery. Results: The CSM-free survival rate at 5 years after NU was 81.2{\%} and 77.8{\%} respectively for pN0 and pNx patients. In univariable analyses pNx vs pN0 status was not associated with worse survival (HR: 1.19; P = .09). After adjustment for all covariates, pNx vs pN0 status still failed to achieve independent predictor status (HR: 0.99; P = .9). Conclusions: We found no survival benefit related to the performance of LND in pN0 patients, relative to pNx patients. Lack of standardized criteria for patients' selection for LND and for pathological lymph node specimen evaluation represents some of the explanation for the observed discrepancy between the current finding and previous findings. Crown",
author = "Giovanni Lughezzani and Claudio Jeldres and Hendrik Isbarn and Shariat, {Shahrokh F.} and Maxine Sun and Daniel Pharand and Hugues Widmer and Philippe Arjane and Markus Graefen and Francesco Montorsi and Paul Perrotte and Karakiewicz, {Pierre I.}",
year = "2010",
month = "1",
doi = "10.1016/j.urology.2009.07.1296",
language = "English",
volume = "75",
pages = "118--124",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - A Critical Appraisal of the Value of Lymph Node Dissection at Nephroureterectomy for Upper Tract Urothelial Carcinoma

AU - Lughezzani, Giovanni

AU - Jeldres, Claudio

AU - Isbarn, Hendrik

AU - Shariat, Shahrokh F.

AU - Sun, Maxine

AU - Pharand, Daniel

AU - Widmer, Hugues

AU - Arjane, Philippe

AU - Graefen, Markus

AU - Montorsi, Francesco

AU - Perrotte, Paul

AU - Karakiewicz, Pierre I.

PY - 2010/1

Y1 - 2010/1

N2 - Objectives: To perform a population-based analysis of the potential staging or prognostic value (or both) of lymph node dissection (LND) in patients without nodal metastases vs no LND. In several previous reports, LND in patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy (NU) was associated with better survival relative to no LND (pNx), even in the absence of pathologically confirmed nodal metastases (pN0). Methods: Within the surveillance, epidemiology, and end results database, we identified 2824 patients treated with NU for UTUC between 1988 and 2004. CSM rates after NU were graphically explored using Kaplan-Meier plots. Univariable and multivariable Cox regression models tested the effect of N0 vs Nx stage on CSM, after adjusting for T stage, tumor grade, age, gender, primary tumor location, type, and year of surgery. Results: The CSM-free survival rate at 5 years after NU was 81.2% and 77.8% respectively for pN0 and pNx patients. In univariable analyses pNx vs pN0 status was not associated with worse survival (HR: 1.19; P = .09). After adjustment for all covariates, pNx vs pN0 status still failed to achieve independent predictor status (HR: 0.99; P = .9). Conclusions: We found no survival benefit related to the performance of LND in pN0 patients, relative to pNx patients. Lack of standardized criteria for patients' selection for LND and for pathological lymph node specimen evaluation represents some of the explanation for the observed discrepancy between the current finding and previous findings. Crown

AB - Objectives: To perform a population-based analysis of the potential staging or prognostic value (or both) of lymph node dissection (LND) in patients without nodal metastases vs no LND. In several previous reports, LND in patients with upper tract urothelial carcinoma (UTUC) treated with nephroureterectomy (NU) was associated with better survival relative to no LND (pNx), even in the absence of pathologically confirmed nodal metastases (pN0). Methods: Within the surveillance, epidemiology, and end results database, we identified 2824 patients treated with NU for UTUC between 1988 and 2004. CSM rates after NU were graphically explored using Kaplan-Meier plots. Univariable and multivariable Cox regression models tested the effect of N0 vs Nx stage on CSM, after adjusting for T stage, tumor grade, age, gender, primary tumor location, type, and year of surgery. Results: The CSM-free survival rate at 5 years after NU was 81.2% and 77.8% respectively for pN0 and pNx patients. In univariable analyses pNx vs pN0 status was not associated with worse survival (HR: 1.19; P = .09). After adjustment for all covariates, pNx vs pN0 status still failed to achieve independent predictor status (HR: 0.99; P = .9). Conclusions: We found no survival benefit related to the performance of LND in pN0 patients, relative to pNx patients. Lack of standardized criteria for patients' selection for LND and for pathological lymph node specimen evaluation represents some of the explanation for the observed discrepancy between the current finding and previous findings. Crown

UR - http://www.scopus.com/inward/record.url?scp=72249118659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72249118659&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2009.07.1296

DO - 10.1016/j.urology.2009.07.1296

M3 - Article

C2 - 19864000

AN - SCOPUS:72249118659

VL - 75

SP - 118

EP - 124

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -